louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06941220: Effect of Mulligan Versus Maitland Mobilization on Lumbar Proprioception in Patients With Chronic Nonspecific Low Back Pain
Official title: Effect of Mulligan Versus Maitland Mobilization on Lumbar Proprioception in Patients With Chronic Nonspecific Low Back Pain
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Low Back Pain
Keywords: mulligan
maitland
proprioception
low back pain
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-04-23
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: mulligan and maitland parallel group
Primary purpose: TREATMENT

Brief summary: this study will be conducted to compare between the effect of mulligan mobilization versus Maitland mobilization on pain ,function and lumbar proprioception in patients with chronic nonspecific low pain

Detailed description: Low back pain (LBP) is considered as one of the most widespread musculoskeletal disorders, impacting over 80% of the world's population, resulting in work absence, medical consultation, a decline in quality of life, and financial burden. Lumbar repositioning error was high around 30° of trunk flexion in individuals with CLB. When lumbar proprioceptive deficiencies arise, the activation pattern of back muscles is disturbed, the mechanics of the spinal unit differs from that of a healthy spine, and the recurrence rate of LBP increases . CLBP is managed using various intervention modalities, including drug therapy and physical therapy approaches . Physical therapy modalities, such as manual therapy, therapeutic exercises, and biopsychosocial techniques, are used for treating LBP. Manual therapy is a common and suggested modality for treating CLBP that has strong evidence. It is employed in physical therapy practice, including Maitland mobilization and Mulligan mobilization. Mulligan mobilization as well as Maitland mobilization has significant effect on pain ,function disability and lumbar repositioning error. But there is gap about which is more beneficial. So we conduct this study to determine which technique is more beneficial for patients

Eligibility criteria: Inclusion Criteria:

* They had interrupted or continuous LBP symptoms for more than 3 months
* both gender

Exclusion Criteria:

* specific LBP
* those who were pregnant
* those with neurological problems

Primary outcomes:
measure: joint position error (lumbar proprioception)
timeFrame: up to four weeks
Secondary outcomes:
measure: pain intensity
timeFrame: up to four weeks
measure: Functional disability
timeFrame: up to four weeks
measure: lumbar range of motion
timeFrame: up to four weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05684120: Mood Lifters for Undergraduates
Official title: Mood Lifters for Undergraduates Project
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Depression
Anxiety
Mood Disorders
Mental Health Wellness 1
Stress
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2023-01-13
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Waitlist control model
Primary purpose: TREATMENT

Brief summary: Large-scale, effective, low-cost, and evidence-based programs that can nimbly translate new research discoveries into prevention and care for psychosocial-based problems are urgently needed since the vast majority of people who need evidence-based care do not receive it.

The purpose of this randomized control trial is to investigate the feasibility and efficacy of a Mood Lifters group template specifically for undergraduate students. Mood Lifters is an effective peer-led program that improves or maintains mental health. It seeks to help people enhance pleasure, engagement, and meaning in their lives while minimizing depression, fear, loneliness, and other negative feelings via a proprietary peer-based program that offers weekly meetings and other flexible support options. One obstacle to providing mental health care in the US is that it is costly to provide one-on-one therapy by a licensed professional. This is particularly true in large group settings with limited resources (counseling centers) and a large need for mental health care, like universities.


Eligibility criteria: Inclusion:

* undergraduate students
* at least 18 years of age

Exclusion criteria include:

* active suicidal thoughts or behavior
* active psychosis
* borderline personality disorder
* active mania
* unwillingness to attend all sessions or treatment types (e.g., unwillingness to attend remote)
* non-undergraduate students.

Primary outcomes:
measure: Patient Health Questionnaire - 9
timeFrame: through study completion, an average of 1 year
measure: Generalized Anxiety Disorder - 7
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Patricia J Deldin, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07025720: Personalized Accelerated Intermittent Theta Burst Stimulation for Post-Acute Suicidal Ideation
Official title: Personalized Accelerated Intermittent Theta Burst Stimulation for Post-Acute Suicidal Ideation
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Major Depressive Disorder (MDD)
Suicidal Ideation
Keywords: TMS
MDD
Suicidal ideation
transcranial magnetic stimulation
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2025-06-17
Enrollment: 25
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn if a fast-acting brain stimulation treatment called transcranial magnetic stimulation (TMS) can help people with depression and suicidal thoughts. The treatment is non-invasive (does not involve surgery or medications), is given over 5 days, and uses brain imaging (MRI) to guide which part of the brain to target. This study tests whether this treatment is a helpful and practical option for patients who recently went to the hospital for suicidal thoughts and were sent home.

We want to see if:

1. This treatment is feasible and acceptable to patients
2. It can reduce depression and suicidal thoughts
3. It can lower the chance of returning to the hospital
4. It affects daily functioning (school, work, relationships)

All participants will undergo 5-days of TMS treatment within 1 week of leaving the hospital. All participants will complete MRI brain scans before and after treatment. They will return for check-ups after 1 week and 4 weeks.


Eligibility criteria: Inclusion Criteria:

* English speaking
* Able to provide informed consent
* ≥ 15 years old
* Discharged within the past week from the ED for chief complaint of SI
* MDD criteria per the Mini International Neuropsychiatric Interview (MINI)

Exclusion Criteria:

* Unable to consent (due to medical condition, psychosis, substance use, etc)
* Active use of benzodiazepines or medications that would interfere with treatment with TMS as per PI discretion
* Active substance use or severe substance use that in the opinion of the PI would interfere with study participation
* Untreated, active psychosis
* Female patient who is breastfeeding, pregnant or who is planning a pregnancy during the study
* Dementia as documented in medical records
* Bipolar disorder as determined by the MINI
* Contraindications to receiving TMS and/or MRI as determined by screening questionnaires
* Participation in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies.

Primary outcomes:
measure: Change in MADRS score
timeFrame: 1 week
Secondary outcomes:
measure: Change in C-SSRS score
timeFrame: 1 week
measure: Hospital readmission rate
timeFrame: 1 week, 1 month
measure: Change in FAST score
timeFrame: 1 week and 1 month
Other outcomes:
measure: Changes in Functional Connectivity
timeFrame: 1 week, 1 month
Locations:
Study officials:
References:
Clinical trial NCT01968720: Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
Official title: A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hyperlipidemias
Hypertriglyceridemia
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Lead sponsor: Catabasis Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2013-10-24
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and efficacy of multiple doses of CAT-2003 in patients with severe hypertriglyceridemia either naive or refractory to current therapy. The study will evaluate effects of CAT-2003 on fasting and postprandial total triglycerides and chylomicron triglyceride levels in patients with severe hypertriglyceridemia.

This is a single-blind study. All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.


Eligibility criteria: Inclusion Criteria:

* Between 18 and 74 years at Screening
* Severe Hypertriglyceridemia (TG ≥ 500 mg/dL). If on lipid lowering therapy including statins, fibrates, and/or omega-3 fatty acids, stable dose for at least 4 weeks prior to Screening
* Body mass index (BMI) ≤ 45 kg/m2

Exclusion Criteria:

* History of any major cardiovascular event within 6 months of Screening
* Type I diabetes mellitus or use of insulin
* History of pancreatitis

Primary outcomes:
measure: Percent change from baseline in fasting triglycerides in patients with severe hypertriglyceridemia
timeFrame: 4 weeks
Secondary outcomes:
measure: Frequency of adverse events
timeFrame: 4 weeks
measure: Absolute and percent change from baseline on postprandial total and chylomicron triglyceride levels
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Miami
country: United States
state: Florida
city: Indianapolis
country: United States
state: Indiana
city: Auburn
country: United States
state: Maine
city: Cincinnati
country: United States
state: Ohio
Study officials:
References:
Clinical trial NCT03299920: Opioid Consumption After Knee Arthroscopy
Official title: Opioid Consumption After Knee Arthroscopy With and Without the Use of New Standardized Patient/Family Instructions for Postoperative Analgesic Use
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Surgical Procedure, Unspecified
Orthopedic Disorder
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2017-10-03
Enrollment: 17
Sex: ALL
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a prospective, randomized trial of patients undergoing outpatient knee arthroscopy surgery and receiving a peripheral nerve block. Patients will be randomized to either receive standard discharge teaching or specialized teaching regarding pain control following a nerve block. Patients will be asked to complete a journal for 5 days recording their pain scores, opioid medication usage, and overall satisfaction with pain control at home.


Eligibility criteria: Inclusion Criteria:

* Patient of age less than 20 years presenting to NCH main campus for knee arthroscopy
* American Society of Anesthesiology physical status I or II

Exclusion Criteria:

* Anterior cruciate ligament repair or reconstruction
* Admission to hospital
* Inability or refusal to receive femoral nerve blockade
* Body mass index \> 99 percentile
* Hydrocodone allergy or intolerance
* Acetaminophen allergy or intolerance
* Non-steroidal anti-inflammatory allergy or intolerance
* Pregnancy
* Interpreter requirement
* Opioid use within 3 months prior to surgery
* Previous knee surgery at WSC after Jan. 1, 2017
* History of opioid abuse or dependence

Primary outcomes:
measure: Number of opioid medication doses taken
timeFrame: Post-op day 5
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
affiliation: Nationwide Children's Hospital
name: Giorgio Veneziano, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02496520: Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
Official title: Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Sarcoma
Central Nervous System Tumor
Keywords: dendritic cell vaccination
sarcoma
central nervous system tumor
childhood
adolescent
immunotherapy
Lead sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Sponsor class: OTHER
First posted: 2015-07-14
Enrollment: 6
Sex: ALL
Minimum age (years): 3
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Phase I/II, open, prospective clinical trial, historically controlled. The objective is to evaluate the safety and, as a secondary measure, the efficacy of an experimental treatment based on a cellular therapy (vaccination with autologous dendritic cells pulsed with tumor lysate) in patients affected of metastatic or relapsed sarcomas or (Central Nervous System) CNS tumors.

Detailed description: Phase I/II, open, prospective clinical trial, historically controlled. Patients affected of metastatic or relapsed sarcomas or (Central Nervous System) CNS tumors will be included. The patients will receive standard treatment and experimental treatment based on a cellular therapy with vaccination with autologous dendritic cells pulsed with tumor lysate. The immunization schedule includes 4 monthly vaccines, 4 bimonthly and quarterly remaining vaccines. The vaccines will be administered intradermally in combination with standard treatment for each type of tumor.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent
* Diagnosis or metastatic or relapsed sarcoma or high grade central nervous system tumor
* From 3 to 40 years
* Surgery feasibility. In the central nervous system tumors, residual tumor after surgery must be minimal.

Exclusion Criteria:

* Toxicity or liver, medullar, renal insufficiency that advise against participation
* Pregnant or breast feeding women
* Diagnosis of other tumor than basal cell squamous carcinoma of the skin or in situ cervix carcinoma
* Immunosuppressive treatment
* Human Immunodeficiency virus (HIV), hepatitis B, hepatitis C or syphilis infection

Primary outcomes:
measure: Number and type of adverse events detected in the follow up as a measure of safety and tolerability
timeFrame: 24 months
Secondary outcomes:
measure: Event free progression, overall survival, time to progression and number and size of existent tumoral lesions as measures of clinical efficacy
timeFrame: 36 months
measure: Humoral and cellular immune response as a measure of the immunogenicity of the vaccine.
timeFrame: 2 weeks to 24 months
measure: Quality of life measured with QLQ-C30, QLQ-BN20 questionnaires.
timeFrame: 36 months
Other outcomes:
Locations:
city: Pamplona
country: Spain
facility: University Clinic of Navarra
state: Navarra
Study officials:
affiliation: CUN
name: Ana Patiño-García, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05824520: Coronary CT-Derived FFR-Guided Strategy Versus Medical Therapy
Official title: Coronary Computed Tomography-Derived Fraction Flow Reserve (FFR)-Guided Invasive Treatment Strategy (ITS) Versus Optimal Medical Therapy (OMT) Alone in Patient With Chronic Coronary Syndrome
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Coronary Artery Disease
Myocardial Ischaemia
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2023-04-21
Enrollment: 1066
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The overall purpose of ACCURATE II trial is to compare the clinical outcomes of CT-derived FFR guided strategy versus medical therapy in patients with chronic coronary syndrome.

Detailed description: ACCURATE II is a prospective, multicenter, randomized clinical trial comparing the clinical outcome and cost-effectiveness of the two management strategies. CT-FFR-guided invasive treatment strategy versus optimal medical therapy, in management of patients with chronic coronary syndrome. The study is powered to detect if the primary endpoint by the CT-FFR-guided strategy is superior to the medical therapy strategy.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years, with at least one vessel has CT-derived FFR≤0.80
* Patients with chronic coronary syndromes
* Signed written informed consent

Exclusion Criteria:

* The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Contrast media (Patients with documented sensitivity to contrast media which can be effectively pre-medicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled)
* Prior percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
* Sinus arrhythmia, cardiogenic shock, or severe heart failure (NYHA≥III)
* Inability or unwillingness to undergo CT scan or coronary angiography
* Patients on hemodialysis or with severe hepatic or renal insufficiency
* Left main coronary artery stenosis ≥ 50%
* Target vessel total occlusion
* Pregnancy or intention to become pregnant during the course of the trial
* Patients with a life expectancy less than 2 years

Primary outcomes:
measure: Major adverse cardiac events (MACE)
timeFrame: 1 year
Secondary outcomes:
measure: Death
timeFrame: 1 year
measure: MI
timeFrame: 1 year
measure: Revascularization
timeFrame: 1 year
measure: Stroke
timeFrame: 1 year
measure: Cost-effectiveness analysis
timeFrame: 1 year
measure: Quality of life assessed by Seattle Angina Questionnaire
timeFrame: 1 year
measure: MACE
timeFrame: 1 month, 2 years, 3 years, 5 years
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Second Affiliated Hospital, School of Medicine, Zhejiang University
state: Zhejiang
Study officials:
affiliation: Second Affiliated Hospital, School of Medicine, Zhejiang University
name: Jian'an Wang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02857920: Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
Official title: Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Malignant Solid Tumour
Keywords: Vascular Endothelial Growth Factor (VEGF) antibody
solid tumor
NK Immunotherapy
Lead sponsor: Fuda Cancer Hospital, Guangzhou
Sponsor class: OTHER
Collaborators: name: Shenzhen Hank Bioengineering Institute
First posted: 2016-08-05
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is the safety and efficacy of Bevacizumab plus allogeneic natural killer (NK) immunotherapy to many kinds of recurrent solid tumors.

Detailed description: By enrolling patients with recurrent solid tumors adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Bevacizumab and NK cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Eligibility criteria: Inclusion Criteria:

* All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
* Body tumor 1-6, the maximum tumor length \< 5 cm
* KPS ≥ 70, lifespan \> 6 months
* Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L

Exclusion Criteria:

* Patients with cardiac pacemaker
* Patients with brain metastasis
* Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Primary outcomes:
measure: PFS
timeFrame: 1 year
measure: OS
timeFrame: 3 years
Secondary outcomes:
measure: Tumor size
timeFrame: 3 months
measure: CTC
timeFrame: 3 months
measure: PD-1
timeFrame: 3 months
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Fuda cancer institute of Fuda cancer hospital
state: Guangdong
Study officials:
affiliation: Fuda Cancer Hospital, Guangzhou
name: Jibing Chen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03110120: Interest of Serratus Plane Block in Postoperative Analgesia for Robot-assisted Surgery
Official title: Interest of Serratus Plane Block in Postoperative Analgesia for Patients Undergoing Robot-assisted Mitral Valve Repair, MIDCAB or Partial Lung Resection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Analgesia
Robotic Surgery
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2017-04-12
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Compare the efficacy of the serratus plane block with local infiltration after thoracic robot-assisted surgery
Primary purpose: TREATMENT

Brief summary: The aim of the study is to compare the analgesia provided by the serratus plane block with local infiltration of the orifices of the trocars after thoracic robot-assisted surgery.

Detailed description: In our hospital, the current practice to provide post operative analgesia for patients scheduled for robot-assisted mitral repair or oncological thoracic surgery is to dispense local anesthetics at the orifices of the trocars at the end of the surgery and to give a Patient Controlled Analgesia (PCA). Some of these patients are not comfortable and we observe a large percentage of chronic pain. Recently we tried to use the Serratus plane block realised before the beginning of the surgery, and it seemed that patients were more comfortable with a lower consumption of morphine. So we decided to perform a double blind, randomized study in this population of patients to compare the analgesia provided by the serratus plane block realized before the beginning of the surgery and the local infiltration of the wound at the end of the surgery.

Eligibility criteria: Inclusion Criteria:

* mitral repair, coronary artery revascularization or thoracic surgery scheduled robot-assisted surgery

Exclusion Criteria:

* non robot-assisted surgery

Primary outcomes:
measure: D0 pain intensity
timeFrame: 1 day
Secondary outcomes:
measure: D1 pain intensity
timeFrame: 3 days
measure: morphine consumption
timeFrame: 5 days
measure: persistence of a chronic pain
timeFrame: 3 months
Other outcomes:
Locations:
city: Bruxelles
country: Belgium
facility: Watremez Christine
Study officials:
affiliation: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
name: Christine Watremez, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: